focus -WSS

focus

author：entertainment 2025-09-30 00:38:22 - browse：8366

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

WSS

Senate panel puts off hardest PBM reforms for another day

PBM reforms clear House panel

Former reverend arrested for allegedly killing 8

CDC Director Mandy Cohen on transparency, trust, and health

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

entertainment

focus

hotspot

Bright Health sells Medicare Advantage business to Molina

What to watch for from Zogenix and Amicus clinical trials

Moonlake's readout produced a cash windfall. Risks remain

PBM reforms clear House panel

Trump demands the U.S. pay no more for drugs than other countries … again

The haunting brain science of long Covid

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Tori Bowie and the unacceptable rates of Black maternal death

CRISPR pioneers react to Casgevy, first gene

hotspot

Democrats decry new health bill for going easy on private equity

Childhood cancer progress stalls for Black, Hispanic kids: Report

NYU radiologists take on the challenge of expensive MRI machines

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Biden warns of ‘dark winter’ during final presidental debate

Will the FTC rein in IQVIA's health data empire?

entertainment

leisure time

leisure time

Wikipedia